<DOC>
	<DOCNO>NCT02938585</DOCNO>
	<brief_summary>This trial conduct China . The aim trial evaluate clinical efficacy turoctocog alfa treatment bleed episode Chinese patient severe haemophilia A ( FVIII≤1 % ) .</brief_summary>
	<brief_title>Efficacy Safety Turoctocog Alfa Prophylaxis Treatment Bleeding Episodes Previously Treated Chinese Patients With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient Age 0 year With diagnosis severe congenital haemophilia A ( FVIII≤1 % ) History exposure day ( ED ) FVIII product fulfil criterion previously treat patient : Patients 12 year : 100 exposure day ( ED ) Patients 12 year : 50 exposure day ( ED ) Inhibitors factor VIII ( ≥0.6 BU ) screen assessed central laboratory Known history FVIII inhibitor</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>